Abstract:Abstract As a multifunctional cytokine that can augment certain T cell responses, IL-4 is being evaluated currently as a possible therapeutic agent in the treatment of cancer patients. In this report, PBMC were isolated from such patients before and after IL-4 therapy and were analyzed for phenotypic and functional alterations. Differential blood counts showed that the relative percentages of lymphocytes and, to a lesser degree, monocytes decreased after treatment with IL-4. However, when phenotypically analyzed by FACS, monocyte numbers generally increased, whereas there was a decrease in lymphocyte numbers. Monocytes taken from patients before therapy and cultured with and without LPS exhibited normal patterns of monokine-specific (IL-1 beta and TNF-alpha) mRNA expression, as well as secretion of peptide. The addition of rIL-4 to these cultures, however, resulted in the down-regulation of both gene expression and peptide release. Although monocytes taken from post-therapy patients also displayed normal patterns of monokine gene expression and cytokine release after stimulation with LPS, they were no longer inhibited by the addition of exogenous rIL-4 in vitro. These data suggest that monocytes become refractory to the inhibitory effects of IL-4 after in vivo exposure to this cytokine. However, when these monocytes were examined for expression of CD14, CD32, and CD64, exogenous IL-4 was observed to decrease markedly the appearance of these markers, regardless of whether the cells were obtained before or after therapy. Furthermore, monocytes from post-therapy patients exhibited reduced production of PGE2 and superoxide anion, compared with cells obtained before therapy. This effect persisted in culture independent of the further addition of exogenous IL-4. These data suggest a dichotomy between the IL-4-dependent mechanisms that regulate monokine production and those that regulate certain other monocyte functions. The exact mechanisms that govern these two pathways are not known. These results have important clinical implications for the use of IL-4 as an immunotherapeutic agent, as well as providing insight into the physiologic role of IL-4.

Stimulatory and Inhibitory Effects of Interleukin (Il)-4 and Il-13 on the Production of Cytokines by Human Peripheral-Blood Mononuclear-Cells - Priming for Il-12 and Tumor-Necrosis-Factor-Alpha Production

Paradoxical priming effects of IL-10 on cytokine production

Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10.

Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells

Administration of recombinant IL-4 to humans regulates gene expression, phenotype, and function in circulating monocytes.

Interaction Between M-CSF and IL-10 on Productions of IL-12 and IL-18 and Expressions of CD14, CD23, and CD64 by Human Monocytes.

[The Effects of M-CSF and IL-10 on IL-12 and IL-18 Production and Expressions of HLA-DR and CD80 by Human Monocytes].

Effect of IL-12 on peripheral blood and lamina propria lymphocyte activation and proinflammatory cytokine secretion in patients with inflammatory bowel disease

IL-10 inhibits cytokine production by activated macrophages.

Transforming growth factor beta 1 and gamma interferon provide opposing signals to lipopolysaccharide-activated mouse macrophages

Gm-Csf Priming Drives Bone Marrow-Derived Macrophages to A Pro-Inflammatory Pattern and Downmodulates Pge(2) in Response to Tlr2 Ligands

Intracellular NF-kB-decrease and IKBα increase in human macrophages following CTLA4-Ig treatment

IL-4 and IL-13 induce equivalent expression of traditional M2 markers and modulation of reactive oxygen species in human macrophages

Interaction Between Macrophage Colony Stimulating Factor and Interleukin 10 on TNF Αand IL 8 Generated by Human Monocytes

Interleukin-4-And Interleukin-13-Enhanced Transforming Growth Factor-Beta 2 Production In Cultured Human Bronchial Epithelial Cells Is Attenuated By Interferon-Gamma

Specific features of human monocytes activation by monophosphoryl lipid A

A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells.

Regulation of Il-12 P40 Promoter Activity in Primary Human Monocytes: Roles of Nf-Kappa B, Ccaat/Enhancer-Binding Protein Beta, and Pu.1 and Identification of A Novel Repressor Element (Ga-12) That Responds to Il-4 and Prostaglandin E-2

Interleukin‐21 Enhances Toll‐like Receptor 2/4‐mediated Cytokine Production Via Phosphorylation in the STAT3, Akt and P38 MAPK Signalling Pathways in Human Monocytic THP‐1 Cells

Comparative Analysis of the Inductive Activity of Interleukin-1α Versus Tumor Necrosis Factor α on G-CSF and GM-CSF Production by Human Vascular Endothelial Cells